[Federal Register Volume 75, Number 206 (Tuesday, October 26, 2010)]
[Notices]
[Page 65658]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-27025]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this 
is notice that on July 12, 2010, Noramco, Inc., Division of Ortho-
McNeil, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801, made 
application by renewal to the Drug Enforcement Administration (DEA) for 
registration as an importer of the basic classes of controlled 
substances listed in schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Raw Opium (9600)...........................  II
Concentrate of Poppy Straw (9670)..........  II
Tapentadol (9780)..........................  II
------------------------------------------------------------------------

    The company plans to import the Raw Opium (9600) and Concentrate of 
Poppy Straw (9670) to manufacture other controlled substances. The 
company plans to import Tapentadol (9780) in intermediate form for the 
bulk manufacture of Tapentadol (9780) which it will distribute to its 
customers.
    No comments, objections, or requests for any hearings will be 
accepted on any application for registration or re-registration to 
import crude opium, poppy straw, concentrate of poppy straw, and coca 
leaves. As explained in the Correction to Notice of Application 
pertaining to Rhodes Technologies, 72 FR 3417 (2007), comments and 
requests for hearings on applications to import narcotic raw material 
are not appropriate.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic classes of controlled 
substances listed in schedule I or II, which fall under the authority 
of section 1002(a)(2)(B) of the Act [21 U.S.C. 952(a)(2)(B)] may, in 
the circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 
1316.47.
    Any such comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than November 26, 2010.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, (40 FR 43745-46), all 
applicants for registration to import a basic class of any controlled 
substances in schedule I or II are, and will continue to be, required 
to demonstrate to the Deputy Assistant Administrator, Office of 
Diversion Control, Drug Enforcement Administration, that the 
requirements for such registration pursuant to 21U.S.C. 958(a); 21 
U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are 
satisfied.

    Dated: October 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator,Office of Diversion Control,Drug 
Enforcement Administration.
[FR Doc. 2010-27025 Filed 10-25-10; 8:45 am]
BILLING CODE 4410-09-P